These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26858355)

  • 1. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
    Sacchi S; Marcheselli R; Bari A; Buda G; Molinari AL; Baldini L; Vallisa D; Cesaretti M; Musto P; Ronconi S; Specchia G; Silvestris F; Guardigni L; Ferrari A; Chiapella A; Carella AM; Santoro A; Di Raimondo F; Marcheselli L; Pozzi S
    Haematologica; 2016 May; 101(5):e196-9. PubMed ID: 26858355
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
    Fowler NH; Nastoupil LJ; Hagemeister FB; Neelapu SS; Fayad LE; LeBlanc D; Samaniego F; Cheah CY
    Haematologica; 2015 Nov; 100(11):e454-7. PubMed ID: 26250576
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
    Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
    Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
    Rosenthal A; Dueck AC; Ansell S; Gano K; Conley C; Nowakowski GS; Camoriano J; Leis JF; Mikhael JR; Keith Stewart A; Inwards D; Dingli D; Kumar S; Noel P; Gertz M; Porrata L; Russell S; Colgan J; Fonseca R; Habermann TM; Kapoor P; Buadi F; Leung N; Tiedemann R; Witzig TE; Reeder C
    Am J Hematol; 2017 May; 92(5):467-472. PubMed ID: 28230270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
    Tuscano JM; Dutia M; Chee K; Brunson A; Reed-Pease C; Abedi M; Welborn J; O'Donnell RT
    Br J Haematol; 2014 May; 165(3):375-81. PubMed ID: 24606326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
    Morschhauser F; Fowler NH; Feugier P; Bouabdallah R; Tilly H; Palomba ML; Fruchart C; Libby EN; Casasnovas RO; Flinn IW; Haioun C; Maisonneuve H; Ysebaert L; Bartlett NL; Bouabdallah K; Brice P; Ribrag V; Daguindau N; Le Gouill S; Pica GM; Martin Garcia-Sancho A; López-Guillermo A; Larouche JF; Ando K; Gomes da Silva M; André M; Zachée P; Sehn LH; Tobinai K; Cartron G; Liu D; Wang J; Xerri L; Salles GA;
    N Engl J Med; 2018 Sep; 379(10):934-947. PubMed ID: 30184451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
    Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
    Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
    Ujjani CS; Jung SH; Pitcher B; Martin P; Park SI; Blum KA; Smith SM; Czuczman M; Davids MS; Levine E; Lewis LD; Smith SE; Bartlett NL; Leonard JP; Cheson BD
    Blood; 2016 Nov; 128(21):2510-2516. PubMed ID: 27697771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
    Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
    Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.
    Ruan J; Shah B; Martin P; Schuster SJ
    Ann Oncol; 2016 Jul; 27(7):1226-34. PubMed ID: 27052651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide, rituximab (R
    Hill BT; Chen Y; Jagadeesh D; Dean R; Koc O; Boughan K; Cooper B; Pohlman B; Caimi P; Smith MR
    Leuk Lymphoma; 2024 Jun; 65(6):768-773. PubMed ID: 38456694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
    Kiesewetter B; Willenbacher E; Willenbacher W; Egle A; Neumeister P; Voskova D; Mayerhoefer ME; Simonitsch-Klupp I; Melchardt T; Greil R; Raderer M;
    Blood; 2017 Jan; 129(3):383-385. PubMed ID: 27879257
    [No Abstract]   [Full Text] [Related]  

  • 14. The evolving role of lenalidomide in non-Hodgkin lymphoma.
    Galanina N; Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
    Cheson BD; Crawford J
    Br J Haematol; 2015 May; 169(4):528-33. PubMed ID: 25752751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
    Luminari S; Goldaniga M; Cesaretti M; Orsucci L; Tucci A; Pulsoni A; Salvi F; Arcaini L; Carella AM; Tedeschi A; Pinto A; Stelitano C; Baldini L
    Leuk Lymphoma; 2016; 57(4):880-7. PubMed ID: 26379040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
    Cheson BD; Morschhauser F; Martin P
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):563-571. PubMed ID: 32303486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide: A Review in Previously Treated Follicular Lymphoma.
    Blair HA
    Drugs; 2020 Sep; 80(13):1337-1344. PubMed ID: 32803669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
    Reddy NM; Greer JP; Morgan DS; Chen H; Park SI; Richards KL
    Leukemia; 2017 Jan; 31(1):241-244. PubMed ID: 27654851
    [No Abstract]   [Full Text] [Related]  

  • 20. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
    Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
    N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.